Draxler Dominik F, Brodard Justine, Zante Björn, Jakob Stephan M, Wiegand Jan, Kremer Hovinga Johanna A, Angelillo-Scherrer Anne, Rovo Alicia
Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Thromb J. 2022 Sep 26;20(1):55. doi: 10.1186/s12959-022-00411-0.
In Covid-19, anticoagulation with heparin is often administered to prevent or treat thromboembolic events. Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin treatment, caused by heparin-dependent, platelet activating anti-platelet factor 4 (PF4)/heparin antibodies. Diagnosis of HIT is based on the combination of clinical parameters, allowing to determine the pretest probability, and laboratory testing for anti-PF4/heparin antibodies and confirmatory functional assays, such as the heparin-induced platelet activation (HIPA) test.We report the case of a patient with severe Covid-19 pneumonia requiring ECMO treatment, who developed recurrent clotting of the ECMO filter and a drop in platelet count under heparin treatment. He was therefore suspected to have HIT and the anticoagulation was switched to argatroban. Despite high clinical probability and high titres of anti-PF4/heparin antibodies, the functional HIPA test was negative. Nevertheless, argatroban was continued rather than to reinstate anticoagulation with heparin. Reevaluation 7 days later then demonstrated a strongly positive functional HIPA test and confirmed the diagnosis of HIT. Under anticoagulation with argatroban the patient gradually improved and was finally weaned off the ECMO.In conclusion, this case highlights the critical importance of clinical judgement, exploiting the 4 T score, given that Covid-19 patients may present a different pattern of routine laboratory test results in HIT diagnostics. The possibility of a false negative HIPA test has to be considered, particularly in early phases of presentation. In cases of a discrepancy with high clinical probability of HIT and/or high titre anti-PF4/heparin antibodies despite a negative HIPA test, a reevaluation within 3 to 5 days after the initial test should be considered in order to avoid precipitant reestablishment of unfractionated heparin, with potentially fatal consequences.
在新冠病毒肺炎(Covid-19)中,常使用肝素进行抗凝治疗以预防或治疗血栓栓塞事件。肝素诱导的血小板减少症(HIT)是肝素治疗的一种严重并发症,由肝素依赖性、血小板活化的抗血小板因子4(PF4)/肝素抗体引起。HIT的诊断基于临床参数的综合判断,以确定预测试概率,以及针对抗PF4/肝素抗体的实验室检测和确证性功能检测,如肝素诱导的血小板活化(HIPA)试验。我们报告了一例患有严重Covid-19肺炎需要体外膜肺氧合(ECMO)治疗的患者,该患者在肝素治疗期间出现ECMO滤器反复凝血和血小板计数下降。因此,怀疑他患有HIT,并将抗凝治疗改为阿加曲班。尽管临床高度怀疑且抗PF4/肝素抗体滴度很高,但功能性HIPA试验结果为阴性。然而,继续使用阿加曲班而不是恢复肝素抗凝治疗。7天后重新评估显示功能性HIPA试验结果呈强阳性,确诊为HIT。在阿加曲班抗凝治疗下,患者逐渐好转,最终脱离ECMO。总之,该病例突出了临床判断的至关重要性,利用4T评分,因为Covid-19患者在HIT诊断中可能呈现不同的常规实验室检查结果模式。必须考虑HIPA试验出现假阴性的可能性,尤其是在疾病早期。在HIT临床高度怀疑和/或抗PF4/肝素抗体滴度很高但HIPA试验为阴性的情况下,应考虑在初次检测后3至5天内进行重新评估,以避免过早重新使用普通肝素,从而可能导致致命后果。